news on OXBT# Stock
E*r
1 楼
FDA confirms lifting of clinical hold on Oxygen Bio's Oxycyte
Mar 31 2014, 08:44 ET
Oxygen Biotherapeutics (OXBT) has received written confirmation that the FDA
has lifted a hold on the clinical trials of the company's Oxycyte treatment
for traumatic brain injury.
The FDA had informed Oxygen Bio of its decision verbally earlier this month.
Oxygen has been enrolling patients in Israel for a Phase IIb study to
evaluate the safety and tolerability of Oxycyte in patients with severe non-
penetrating traumatic brain injury.
Shares jump 10.6% premarket. (PR)
http://seekingalpha.com/news/1651693-fda-confirms-lifting-of-cl
Mar 31 2014, 08:44 ET
Oxygen Biotherapeutics (OXBT) has received written confirmation that the FDA
has lifted a hold on the clinical trials of the company's Oxycyte treatment
for traumatic brain injury.
The FDA had informed Oxygen Bio of its decision verbally earlier this month.
Oxygen has been enrolling patients in Israel for a Phase IIb study to
evaluate the safety and tolerability of Oxycyte in patients with severe non-
penetrating traumatic brain injury.
Shares jump 10.6% premarket. (PR)
http://seekingalpha.com/news/1651693-fda-confirms-lifting-of-cl
